- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02078128
To Study the Effect of β-glucans on Wound Healing
March 3, 2014 updated by: National Taiwan University Hospital
The purpose of this study is to determine the effect of β-glucans on wound healing.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The structure of βeta-glucan (β-glucans) is a pathogen associated molecular patterns (pathogen-associated molecular patterns, PAMPs), widely present in the cell walls of plants, bacteria, yeasts, fungi, mushrooms and algae.
Modern has been reported in the literature that β-glucan can enhance the immune system of animals, and to enhance the function of the animal against bacterial, fungal and viral infections, and cancer.In this study, the use of β-glucan to enhance the biological characteristics of the non-specific immunity, to explore the impact of postoperative patients with wound healing and infection rates.The observation of the healing process to take the Leather District wounds (5 ~ 200 cm2).
The experiments were carried out for 18 months, were observed record the following three: (1) the rate of wound healing, (2) The rate of infection assessment: record length of time and the point in time at all levels of antibiotic use also observe the wound change (redness, swelling, heat, pain).(3)
days of hospitalization, and spend statistics.
Using unpaired student's t-test analysis, group data whether the differences between groups of experimental data.
represents a statistically significant when p <0.05.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Total burn area under 20%, two to three degree burn and need skin-grafting.
- Subjects don't have other diseases.
- Subjects' age between 20 to 60.
Exclusion Criteria:
- Subjects with hypersensitivity.
- Subjects with Autoimmune disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: oral beta-glucans
Daily give kg per day to 30 mg of β-glucan (30mg/kg/day), taking to the wound healed.
|
30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
Other Names:
|
|
Placebo Comparator: oral sugar powder
control group, daily give and the glucose powder 30 mg per kilogram of body weight (30mg/kg/day) a day, taking to the wound healed.
|
30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wound healing percentage
Time Frame: every Monday and Thuresday for the duration of hospital stay, an expected average of 3 weeks
|
record data by taking picture
|
every Monday and Thuresday for the duration of hospital stay, an expected average of 3 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Eng Kean Yeong, National Taiwan University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2011
Primary Completion (Actual)
August 1, 2011
Study Completion (Actual)
February 1, 2013
Study Registration Dates
First Submitted
September 17, 2012
First Submitted That Met QC Criteria
March 3, 2014
First Posted (Estimate)
March 5, 2014
Study Record Updates
Last Update Posted (Estimate)
March 5, 2014
Last Update Submitted That Met QC Criteria
March 3, 2014
Last Verified
March 1, 2014
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 201105013MB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burns
-
Fondation Ophtalmologique Adolphe de RothschildNot yet recruiting
-
MediWound LtdUnknownBurns, Upper Extremity | Burns, Lower ExtremitySlovakia
-
Singapore General HospitalUnknownAcute Thermal BurnsSingapore
-
RenovaCare, IncActive, not recruitingBurns | Burns Second Degree | Burns Deep Second DegreeUnited States
-
American Scitech InternationalJohnson & JohnsonUnknownBurns | Electric BurnsUnited States
-
Sun Yat-sen UniversityCompleted
-
Hennepin Healthcare Research InstituteNot yet recruiting
-
Buckinghamshire Healthcare NHS TrustNot yet recruitingBurns Multiple
-
Virginia Commonwealth UniversityNot yet recruiting
-
Riphah International UniversityActive, not recruiting
Clinical Trials on oral sugar powder
-
National Institute of Cardiology, Laranjeiras,...Completed
-
Kantonsspital AarauTerminatedUrinary Tract InfectionsSwitzerland
-
Napo Pharmaceuticals, Inc.RecruitingRare Diseases | Congenital Disorders | Microvillus Inclusion DiseaseUnited States, Italy, United Arab Emirates
-
Duke UniversityVifor PharmaCompletedEnd Stage Renal Disease | HyperkalemiaUnited States
-
Integrative Skin Science and ResearchCodex LabsCompletedSkin Diseases | Acne Vulgaris | Acneiform Eruptions | Sebaceous Gland DiseasesUnited States
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences InstituteCompletedIntestinal HealthUnited States
-
University of MinnesotaCystic Fibrosis FoundationCompletedCystic FibrosisUnited States
-
Queens College, The City University of New YorkCompletedDiabetes | PreDiabetesUnited States
-
Dr Maryam AslamCMH GujranwalaCompletedCesarean Section | Gum Chewing | Gut MotilityPakistan
-
Lument ABQ Clinical Research ABCompleted